Financial Data and Key Metrics Changes - In Q4 2025, worldwide sales reached $24.6 billion, a 7.1% increase despite a 650 basis point headwind from Stelara [17] - For the full year 2025, worldwide sales were $94.2 billion, reflecting a 5.3% increase, with U.S. growth at 6.9% and international growth at 3.4% [18] - Net earnings for Q4 were $5.1 billion, with diluted earnings per share at $2.10, compared to $1.41 a year ago [18] - Full year 2025 net earnings were $26.8 billion, with diluted earnings per share at $11.03, significantly up from $5.79 the previous year [19] Business Line Data and Key Metrics Changes - Innovative Medicine reported Q4 sales of $15.8 billion, a 7.9% increase, with notable growth in oncology and immunology [20] - In oncology, Darzalex grew 24.1%, while Carvykti achieved sales of $555 million with a growth of 63.2% [20] - Immunology saw Tremfya grow 65.4%, while Stelara declined 48.6% due to biosimilar competition [21] - MedTech sales for the year were $34 billion, with operational growth of 5.4%, driven by cardiovascular and surgical segments [13] Market Data and Key Metrics Changes - U.S. sales growth was 7.5% in Q4, while international sales grew by 6.6% [17] - The cardiovascular segment delivered 15% operational sales growth, with Abiomed and Shockwave showing strong performance [13] - Surgical vision grew 10.8%, driven by new product innovations and demand for premium intraocular lenses [24] Company Strategy and Development Direction - The company plans to separate its orthopedics business by mid-2027, focusing on high-growth areas [30] - Investments of over $32 billion in R&D and M&A were made in 2025, including acquisitions of Intra-Cellular Therapies and HALDA Therapeutics [6] - The company aims for double-digit growth by the end of the decade, supported by a strong portfolio and pipeline [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving faster growth in 2026 compared to 2025, with a line of sight to double-digit growth [6] - The company anticipates operational sales growth in 2026 to be between 5.7% and 6.7%, with a midpoint of $100 billion [31] - Management highlighted the strength of their portfolio and pipeline as key drivers for future growth [41] Other Important Information - The company ended 2025 with approximately $20 billion in cash and marketable securities, and $48 billion in debt [30] - A net interest expense of $300 million to $400 million is expected for 2026 [33] - The effective tax rate is projected to be between 17.5% and 18.5% for 2026 [34] Q&A Session Summary Question: Overview of growth prospects and key levers for double-digit growth - Management highlighted the strength of the portfolio and pipeline, focusing on oncology, immunology, and MedTech as key growth areas [40][41] Question: MedTech market dynamics and growth expectations - Management does not expect the loss of ACA subsidies to materially impact MedTech performance, with a focus on clinical capacity driving growth [48] Question: Margin progression and relationship to top-line growth - Management indicated that margin improvements will align with sales growth, with expectations for at least 50 basis points of improvement in 2026 [55] Question: Vision care market health and performance - Management noted strong underlying demand in the contact lens category, with robust growth driven by new product launches [58][59]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - The U.S. biotech industry is increasingly dependent on China, which has become a critical player in drug development and innovation [4][5][18] - China's role has evolved from contract research and manufacturing to significant contributions in novel drug discovery and licensing [17][19] Industry Overview - Major biotech hubs in the U.S. include Boston, San Francisco, and San Diego, while China has developed significant life-science clusters in cities like Shanghai and Beijing [3] - Zhangjiang Science City in Shanghai hosts over 1,700 biomedical companies, including major global pharmaceutical firms [3] Financial Landscape - The average cost for a big pharma company to develop a drug in 2024 is $2.23 billion, while biotech startups require a median investment of $304.1 million to develop FDA-approved biologics [5][6] - U.S. biotech funding has declined, with only 8.3% of venture funding going to biotech in 2025, the lowest in over 20 years [6][7] Research and Development - China conducted nearly one-third of the world's clinical trials in 2024, benefiting from lower operational costs and a unified data system [13][15] - The National Medical Products Administration (NMPA) has significantly increased its capacity, clearing a backlog of drug applications much faster than the FDA [15] Licensing and Innovation - In 2024, the value of drugs licensed from China to the West reached $48 billion, a 15-fold increase since 2020, with Chinese firms accounting for nearly a third of large licensing deals [18][19] - The share of global licensing deals from Chinese companies increased from 5% in 2019 to 48% in 2025, while U.S. companies' share dropped from 55% to 29% [18] Regulatory Environment - The U.S. government has enacted the BIOSECURE Act, restricting federal agencies from purchasing biotech products from certain companies, signaling a shift in the regulatory landscape [21][24] - The Act reflects the growing perception of biotechnology as a matter of national security, potentially altering the dynamics of U.S.-China biotech relations [24]

th January 21, 2026 Cautionary note on Forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate ...

Market Overview - Futures have reversed modest overnight gains, with S&P futures down 0.1% and Nasdaq futures down 0.3% as small caps outperform for a record 12th day in a row [1] - The market mood remains shaky, with a significant drop in liquidity as top of book collapsed 60% overnight [4] - Gold continues to hit new highs, approaching $4,900 per ounce, while bond yields are 1-2 basis points lower [1][8] Corporate News - Biohaven (BHVN) rises 3% after an upgrade to outperform by RBC due to supportive data [5] - Halliburton (HAL) climbs 2% after reporting fourth-quarter adjusted earnings per share that beat analyst estimates [5] - Kraft Heinz (KHC) declines 5% as Berkshire Hathaway may sell some or all of its stake in the company [5] - Nathan's Famous (NATH) rises 8% after Smithfield Foods agreed to buy the company for $102 per share [5] - Netflix (NFLX) falls 7% after forecasting first-quarter earnings below analyst estimates and pausing share buybacks [5] Economic Indicators - The US economic calendar includes October construction spending and December pending home sales, with expectations of a 0.1% increase and a 0.25% decrease respectively [18][38] - Inflation in the UK rose to 3.4% in December, slightly above expectations, driven by higher tobacco prices and airfares [27] Geopolitical Developments - President Trump's speech at the World Economic Forum is anticipated to address various topics, including trade and tariffs, amid ongoing tensions regarding Greenland [6][30] - The Supreme Court is set to hear arguments regarding Trump's ability to fire Federal Reserve Governor Lisa Cook, coinciding with a criminal investigation into Fed Chair Jerome Powell [11][25] Sector Performance - European stocks drifted lower, with the Stoxx 600 down 0.6%, weighed down by financials and tech, while materials and luxury names outperformed [13][26] - The Russell 2000 is outperforming the Magnificent Seven by more than 10% year-to-date, indicating a rotation in market leadership [9]

Core Viewpoint - A court-appointed special master has recommended that women suing Johnson & Johnson (J&J) over claims that the company's talc products caused ovarian cancer be allowed to present expert testimony supporting that link, moving the litigation closer to trial [1][2]. Group 1: Litigation Overview - The ongoing litigation includes over 67,500 lawsuits in federal court in New Jersey, with the first trial potentially occurring later this year [2]. - U.S. District Judge Michael Shipp is overseeing the litigation and has brought in retired Judge Freda Wolfson to evaluate expert testimony [3]. - Wolfson's 658-page decision allows plaintiffs' experts to testify about a causal link between J&J talc products and cancer, which J&J disputes [4]. Group 2: Expert Testimony - Wolfson found that the plaintiffs' experts used reliable methodologies, demonstrating a statistically significant association between genital talc powder use and ovarian cancer [5]. - Testimony from J&J's experts will also be allowed to counter the plaintiffs' claims [5]. - Wolfson's role was to assess the reliability of the experts' methods rather than their conclusions [6]. Group 3: Company Response and Historical Context - J&J's Vice President of Litigation criticized Wolfson's ruling as erroneous and stated the company would appeal [7]. - The company has faced significant legal challenges, including attempts to resolve litigation through bankruptcy, which were rejected by federal courts [13]. - J&J has a mixed record in state courts, with some verdicts as high as $4.69 billion awarded to plaintiffs [15]. Group 4: Additional Legal Challenges - J&J has also faced cases alleging its talc products caused mesothelioma, with substantial verdicts in recent months, including over $1.5 billion in Baltimore [16]. - The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product [9].

Group 1 - The fourth quarter earnings season is gaining momentum, with major financial institutions like Charles Schwab and regional banks such as Fifth Third set to report results, alongside Netflix and Intel, which are expected to be focal points of the earnings calendar [1][5] - An optimistic consensus is emerging, with 7% of S&P 500 companies having reported fourth quarter results as of January 16, and analysts projecting an 8.2% increase in earnings per share for the quarter, marking the potential for the 10th consecutive quarter of annual earnings growth for the index [2] - Analysts had initially anticipated an 8.3% increase in earnings per share heading into the reporting period, a decrease from the previous quarter's 13.6% growth rate, but expectations have been raised recently, particularly for technology companies that have been key drivers of earnings growth [3] Group 2 - The current earnings season is expected to test the improved stock market breadth observed at the beginning of 2026, with ongoing themes from 2025, such as artificial intelligence and economic policies, continuing to influence market dynamics [4] - This week's earnings releases will also include reports from notable companies such as United Airlines, 3M Company, D.R. Horton, Johnson & Johnson, GE Aerospace, Procter & Gamble, Abbott Laboratories, and Capital One [5]

Core Viewpoint - Johnson & Johnson (JNJ.US) reported strong Q4 2025 earnings, exceeding Wall Street expectations, driven by robust sales in innovative medicines and medical devices [1][3][4] Group 1: Q4 Performance - The company achieved a quarterly profit of approximately $6 billion, reflecting a year-over-year increase of 22%, with earnings per share at $2.46, slightly above analysts' expectations of $2.44 [1] - Q4 revenue reached $24.56 billion, surpassing the anticipated $24.16 billion, marking a year-over-year growth of 9.1% [1] - The Innovative Medicine segment saw a 10% increase in sales to $15.76 billion, exceeding the expected $15.37 billion [1] Group 2: Medical Devices and Future Outlook - The medical devices segment reported a 7.5% increase in sales to $8.8 billion, outperforming the management's prior estimate of approximately $8.69 billion, driven by strong performance in cardiac devices [3] - For 2026, the company forecasts operational sales between $99.5 billion and $100.5 billion, higher than the consensus estimate of $98.9 billion [4] - Adjusted earnings per share for 2026 are projected to be between $11.43 and $11.63, slightly above analysts' expectations of $11.45 [4] Group 3: Challenges and Market Impact - The company faces challenges, including tariff uncertainties affecting its medical devices segment and increased competition for its psoriasis drug Stelara, which saw a larger-than-expected sales decline [4][5] - Despite the optimistic earnings forecast, the stock price initially dropped over 3% in pre-market trading but later recovered, with a year-to-date increase of over 5% [5] - Johnson & Johnson's market capitalization stands at $525.7 billion, maintaining a significant weight in the S&P 500 index, influencing overall market trends [5] Group 4: Legal Issues - A court-appointed special monitor recommended allowing expert testimony linking the company's talc products to ovarian cancer, with a significant trial expected to begin in late 2026 [6]

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data | (Unaudited; Dollars in Millions) | | | FOURTH QUARTER | | | | --- | --- | --- | --- | --- | --- | | | | | | Percent Change | | | Sales to customers by geographic area | 2025 | 2024 | Total | Operations | Currency | | U.S. | $14,195 | 13,204 | 7.5 % | 7.5 | — | | Europe | 5,598 | 4,921 | 13.8 | 5.2 | 8.6 | | Western Hemisphere excluding U.S. | 1,271 | 1,135 | 12.0 | 11.0 | 1.0 | | Asia-Pacific, Africa | 3,500 | 3,260 | 7.4 | 7.2 | 0.2 ...

Core Insights - Isomorphic Labs, an AI pharmaceutical company spun off from DeepMind, has announced a collaboration with Johnson & Johnson's Janssen Pharmaceuticals to combine AI design capabilities with drug development expertise [1][5] - The partnership will focus on "cross-modal, multi-target research collaboration," with Isomorphic responsible for computer predictions and design, while the U.S. team will handle experimental testing and project development [1][5] - Isomorphic has also signed significant research collaborations with Novartis and Eli Lilly, totaling over $3 billion [6] Company Developments - Isomorphic Labs was established at the end of 2021 and is based on the technology and team from the renowned AlphaFold2 [6] - The company recently raised $600 million in funding led by Thrive Capital, with participation from GV and Alphabet, aimed at supporting its AI drug design engine and advancing internal projects into clinical stages [5] - In May 2024, Isomorphic and DeepMind jointly released AlphaFold3, a revolutionary tool for predicting the structure and interactions of all life molecules, enhancing drug development capabilities [8] Future Outlook - The founder of Isomorphic, Demis Hassabis, emphasized in a recent interview that AI is the ultimate tool for scientific exploration, capable of solving complex scientific challenges, with AlphaFold's success as a testament [10] - There is optimism that AI will usher in a new golden age of scientific discovery across various fields, including materials science, physics, mathematics, and weather forecasting [10]